Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06607432 · ClinicalTrials.gov registry record · NA

Temporal Interference Stimulation for Social Cognition

A NA study of Healthy (Controls), sponsored by Columbia University.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06607432: Recruiting NA study of Healthy (Controls), sponsored by Columbia University.

NCT06607432 is a NA study of Healthy (Controls) that is actively recruiting participants, run by Columbia University. The registered enrollment target is 30 participants, below the 119-participant average among 16 other Healthy (Controls) trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06607432, a NA study of Healthy (Controls), is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The long-term goal of this project is to evaluate whether a procedure termed transcranial interference stimulation (tIS) may be useful in the future in the treatment of severe neuropsychiatric disorders such as schizophrenia. The purpose of this stage of the project is to evaluate the safety and tolerability of tIS administration in healthy volunteers. This study involves 30 healthy participants without known psychiatric illness, who will participate in groups of 10. The dose of tIS will be escalated progressively across doses. Functional magnetic resonance imaging (fMRI), magnetic resonance spectroscopy (MRS) and side effect checklists will be used to assess tIS safety/tolerability at each dose. In addition, electroencephalogram (EEG) will be collected simultaneously with tIS and used to assess target engagement. Face emotion recognition (FER) data will also be collected, but will be used for feasibility assessment only. If successful, these studies will form the basis for future studies in schizophrenia.

Primary Outcome

Pulvinar nucleus (PuN) activation levels as determined by functional magnetic resonance imaging (fMRI, safety) These analyses assess the degree to which presentation of a stimulus designed to activate the pulvinar nucleus leads to an increase in local activation as reflected in the fMRI response. Units will be % increase in signal strength during stimulation vs. baseline.

Conditions Studied

Interventions

  • DEVICE Transcranial Interference Stimulation (tIS)
  • OTHER Sham tIS

Study Locations (1)

New York

  • Columbia University Irving Medical Center/NewYork-Presbyterian Hospital (CUIMC/NYPH) - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-03-03
Est. Completion 2028-02-29
Phase NA
Columbia University

958 total trials

What NCT06607432 shows while recruiting

NCT06607432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 119-participant average among 16 other Healthy (Controls) trials with a reported enrollment target (75% lower).

The record links to 1 condition, with Healthy (Controls) appearing as the primary indexed condition, and to 2 interventions - of which Transcranial Interference Stimulation (tIS) is the first listed.

NCT06607432 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06607432 about?

NCT06607432 is a clinical study titled "Temporal Interference Stimulation for Social Cognition". The long-term goal of this project is to evaluate whether a procedure termed transcranial interference stimulation (tIS) may be useful in the future in the treatment of severe neuropsychiatric disorders such as schizophrenia. The purpose of this stage of the project is to evaluate the safety and tol...

What is the current status of trial NCT06607432?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-03-03. Estimated completion is 2028-02-29.

What conditions does trial NCT06607432 study?

This clinical trial studies the following conditions: Healthy (Controls).

What interventions are being tested in trial NCT06607432?

The interventions under investigation include: Transcranial Interference Stimulation (tIS) (DEVICE), Sham tIS (OTHER).

Who is sponsoring clinical trial NCT06607432?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06607432 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy (Controls)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06607432's enrollment target sits among peer trials

30 15th of 16 higher than 2 of 16 other Healthy (Controls) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy (Controls) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06607432, the US trial registry maintained by the National Library of Medicine. NCT06607432 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.